title: Serum lipid physiology and the influence of glaucoma medications.
abstract: Understanding the effect of serum lipid levels on risk factors for coronary heart disease and how they are influenced by medical therapy may lead to overall better care of the glaucoma patient. Elevated low-density lipoprotein and total cholesterol levels are major risk factors for heart disease. In contrast, high-density lipoprotein (HDL) is protective for heart disease. beta-adrenergic blockers, a class of medicines used to treat glaucoma, may influence serum lipid levels. Oral nonselective beta-adrenergic blockers reduce HDL cholesterol by 19% and increase triglycerides by 20-40%. Furthermore, topical nonselective beta-adrenergic blockers also decrease serum HDL and worsen the total cholesterol/HDL ratio. However, beta-blockers with intrinsic sympathomimetic activity appear to be lipid neutral. At present, there is no clear clinical evidence to indicate that changes in serum lipids with use of topical beta-adrenergic blockers significantly affect the clinical course of the patient. Little information is available for other classes of medicines used topically to treat glaucoma. However, oral preparations of prostaglandins, alpha-adrenergic agonists, angiotensin-converting enzyme inhibitors, and calcium channel blockers do not adversely affect serum lipid levels. Further study is required on newer glaucoma preparations to determine their specific actions on lipid levels. Additionally, further work is required to understand the significance of not only the adverse effect of beta-adrenergic blockers on lipid levels, but their overall effect on long-term cardiac morbidity and mortality.
authors.affiliation: Pharmaceutical Research Corporation, Charleston, Carolina Eye Institute, South Carolina 29412, USA.
authors.forename: W C
authors.initials: WC
authors.lastname: Stewart
authors.forename: J
authors.initials: J
authors.lastname: Osterman
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D003327:Coronary Disease / Q000097:blood / Q000139:chemically induced; D005902:Glaucoma, Open-Angle / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000139:chemically induced; D008055:Lipids / Q000097:blood*; D012307:Risk Factors
chemical_list: D000319:Adrenergic beta-Antagonists; D008055:Lipids